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Abstract
Purpose of Review—The goal of this review is to highlight the potential of induced pluripotent 
stem cell (iPSC)-based modeling as a tool for studying human cardiovascular diseases. We present 
some of the current cardiovascular disease models utilizing genome editing and patient-derived 
iPSCs.
Recent Findings—The incorporation of genome-editing and iPSC technologies provides an 
innovative research platform, providing novel insight into human cardiovascular disease at 
molecular, cellular, and functional level. In addition, genome editing in diseased iPSC lines holds 
potential for personalized regenerative therapies.
Summary—The study of human cardiovascular disease has been revolutionized by cellular 
reprogramming and genome editing discoveries. These exceptional technologies provide an 
opportunity to generate human cell cardiovascular disease models and enable therapeutic strategy 
development in a dish. We anticipate these technologies to improve our understanding of 
cardiovascular disease pathophysiology leading to optimal treatment for heart diseases in the 
future.
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While heart disease remains a leading cause of morbidity and mortality in the world, the 
discovery of fundamental disease insights and transformative new therapies have not kept up 
with steady increase in disease prevalence. For instance, congenital heart disease is one of 
the most complicated and lethal diseases, yet its etiology remains mostly unknown, due in 
part to limitation in current disease models. Here, we review new findings in human 
cardiovascular disease, with a focus on patient-derived stem cell models and genome-editing 
technology.
Historical Cardiovascular Disease Models
According to the American Heart Association, cardiovascular disease accounted for one in 
three deaths in the USA. To meet the tremendous need for transformative new therapies for 
heart disease, it is essential to improve our understanding of its pathophysiology. Because 
human cardiovascular pathology is complex, with multiple contributing factors, both genetic 
and environmental, it is important to develop disease models that optimally recapitulate key 
aspects of cardiovascular disease in human. In the past three decades, important insights into 
cardiovascular disease pathophysiology have been provided through animal models. For 
example, the use of transgenic and genetic knockout mice allows for examination of the 
effects of genetic manipulation of a single or very small number of genes involved in heart 
development or physiology. However, major differences in human and rodent cardiovascular 
systems present important limitations [1, 2]. Due to species-specific differences, a genetic 
perturbation in mice may not accurately reflect human disease processes. Also, many adult-
onset diseases or those having polygenic contributions are not faithfully recapitulated using 
mouse models. Thus, the direct relevance of many mouse models to human cardiovascular 
diseases is often uncertain [3]. Alternatively, large animal models of human heart disease 
have been utilized based on the premise that they are more physiologically and clinically 
similar to humans than the mice. For instance, a dog’s cardiovascular physiology is similar 
to humans in many respects, including the heart rate, blood pressure, and the contributions 
of sympathetic and parasympathetic nervous system [4]. Humans and dogs are also highly 
similar at the cellular and molecular levels, including the transmural and apicobasal 
distribution of key ion channels in the heart [5, 6]. However, there are several important 
limitations to large animal models including much higher maintenance costs and longer 
gestation time, making large animals less optimal as genetic models [7, 8]. For obvious 
reasons, the use of human heart tissue for experimentation is highly restricted. Lastly, 
isolated human or animal cardiomyocytes are in a highly catabolic state, rapidly approaching 
death within a few days of culture.
Given the limitations of current models, the emergence of human pluripotent stem cells, 
capable of multiplying indefinitely and differentiating to all tissue types such as the 
cardiovascular cells, has raised substantial interest in using them to study human 
cardiovascular diseases. This revolutionary technology, together with equally revolutionary 
advances in genomic editing, has provided an unprecedented opportunity for modeling 
human cardiovascular diseases.
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Induced Pluripotent Stem Cells as Cardiovascular Disease Models
Pluripotent embryonic stem cells (ESCs) were first discovered in the blastocyst of 
developing mouse embryos [9, 10] and subsequently in human embryos [11]. The ESCs 
possessed the ability to continuously replicate themselves and to differentiate to all tissue 
types. Despite their vast potential, however, the human ESCs were not widely adopted due to 
significant technical limitations and ethical concerns regarding the destruction of human 
embryos. In 2006, by introducing the four transcription factors OCT4, SOX2, LKF4, and c-
MYC, Shinya Yamanaka and colleagues perfected the method to reprogram terminally 
differentiated somatic cells into pluripotent stem cells, which they termed induced 
pluripotent stem cells (iPSCs) [12–14]. Like ESCs, the iPSCs are pluripotent, capable of 
differentiating to virtually all cell types [15]. However, as opposed to ESCs, iPSCs could be 
generated from readily accessible tissue samples, including skin, blood, and urine [16–18]. 
While the early efforts involved the delivery of the reprogramming transcription factors via 
retroviruses, which posed tumorigenic potential by genome integration, more recent 
reprogramming efforts involve vectors that do not integrate into the genome [19, 20]. Based 
on these and other advances, reprogramming a patient’s cells to generate iPSCs as a 
renewable source of autologous donor cells and tissues has become commonplace.
The iPSC technology, along with advances in techniques for directed differentiation into 
cardiovascular cells, has already made important impact in cardiovascular biology. Among 
the first cardiac diseases to be modeled using this technology were the inherited arrhythmia 
syndromes since electrical abnormalities can be readily detected in hiPSC-CMs and because 
mouse, whose heart beats 10× faster than human heart, is suboptimal for modeling human 
arrhythmias [21, 22]. For example, long QT syndrome (LQTS) is a class of arrhythmias 
associated with delayed repolarization of cardiomyocytes that increases the risk of Torsade 
de Pointes (TdP), a ventricular arrhythmia which can cause sudden death [23–26]. While 
most LQTS is congenital, LQT and TdP can be triggered by certain drugs that can delay 
repolarization in susceptible individuals [27]. In 2010, Moretti and colleagues [22] 
successfully generated iPSC-CMs from patients with type 1 LQTS (LQTS1), caused by an 
autosomal dominant missense mutation (R190Q), in the KCNQ1 gene, which encodes the 
repolarizing potassium channel responsible for the slow delayed rectifier IKS current. 
Consistent with a defective repolarization, the action potential duration was prolonged in 
LQTS1 iPSC-CMs compared to controls from healthy donors. At the cellular level, LQTS1 
iPSC-CMs exhibited a dominant negative trafficking defect in the potassium channel that 
caused a 70–80% diminution of the IKS current, resulting in defective repolarization. In 
another study, Gaborit and colleagues generated iPSCs from squamous epithelial cells in 
urine samples of patients with type 2 LQTS (LQTS2), caused by a A561P mutation in the 
KCNH2 gene, which encodes the potassium channel responsible for the rapid delayed 
rectifier IKr current [28]. The electrophysiological analysis of iPSC-CMs demonstrated that 
IKr was decreased by 50–60%, leading to a prolonged action potentials compared to 
controls. Additionally, LQTS2 iPSC-CMs exhibited significantly increased 
arrhythmogenicity when treated with clobutinol, an antitussive drug associated with drug-
induced TdPs. Another model of LQTS utilized iPSC-CMs derived from an LQTS patient 
with an F142L mutation in the CALM1 gene, encoding calmodulin1 [29]. This study found 
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that the mutant iPSC-CMs exhibited impaired calcium-dependent inactivation of the L-type 
calcium channel current (ICAL), resulting in prolonging repolarization associated with IKs 
inhibition and delayed sodium channel (INa) inactivation. Interestingly, the electrical 
abnormalities in the mutant CAML1 iPSC-CMs were exacerbated by β-adrenergic 
stimulation, consistent with what is observed in these patients [29]. Lastly, a study 
examining the effects of drugs associated with LQT and TdP on human iPSC-CMs supports 
the growing body of evidence for the role of the late sodium current in drug-induced 
arrhythmias [27]. Thus, patient-derived iPSC-CMs have proven valuable for studying 
pathogenesis of both inherited and drug-induced arrhythmias in man.
iPSC-CMs models have been developed for various cardiomyopathies, including familial 
dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). Wu and 
colleagues demonstrated that iPSC-CMs derived from familial DCM patients with a 
mutation in the TNNT2 gene, encoding sarcomeric protein cardiac troponin T, recapitulated 
much of the morphological and functional defects seen in these patients. The mutant iPSC-
CMs had altered beating rates and contraction, along with sarcomere disarray seen in the 
heart of DCM patients [30]. The Wu group’s study of left ventricular non-compaction 
cardiomyopathy utilizing patient-derived iPSC-CMs determined that the mutation in the 
transcription factor TBX20 recapitulates pathological phenotypes at the single-myocyte level 
and demonstrated the relationship between defective TBX20 function and the aberrant 
regulation of its down-stream target RDM16 via altered TGF-β signaling [31].
Patient-derived iPSC-CMs have also contributed to a better understanding of HCM 
pathogenesis. For example, the Wu group demonstrated that iPSC-CMs derived from 
familial HCM patients due to a R663H mutation in the MYH7 gene, encoding the β-myosin 
heavy chain, exhibited many hallmarks of HCM such as hypertrophy, abnormal calcium 
handling, increased arrhythmia propensity, increased β-myosin/α-myosin ratio, increased 
atrial natriuretic factor expression and calcineurin activation [32]. Blockage of Ca2+ entry by 
L-type Ca2+ channel blocker verapamil abrogated much of the HCM phenotype in iPSC-
CMs, suggesting that elevated intracellular calcium plays a central role in HCM 
pathogenesis [33]. Importantly, this study provides intriguing insights to a potential 
pharmaceutical treatment of HCM. Taken together, these examples exhibit the importance of 
human cardiovascular models and the potential of iPSC technology for modeling diseases 
and developing therapeutic strategies.
Genome Editing for the Study of Cardiovascular Biology
Revolutionary advances in the ability to precisely edit genomic DNA will greatly aid 
cardiovascular research. Genome-editing techniques are classified based on the site-specific 
nucleases utilized: the meganucleases, zinc finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and the clustered regularly interspaced short palindromic 
repeat (CRISPRs)-associated nuclease Cas9 (CRISPR/Cas9) [34–36]. These nucleases 
create sequencespecific double-stranded breaks (DSB), which are then repaired in the cell by 
two distinct endogenous repair systems: non-homologous end-joining (NHEJ) or homology-
directed repair (HDR). NHEJ repair often results in insertions or deletions (indels) at the 
DSB sites, typically resulting in frameshift mutations [37]. Thus, NHEJ can generate loss-
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of-function mutations in the targeted genes. By contrast, in HDR, a single- or double-
stranded DNA template is utilized to repair the break site. Using template repair of DSB, 
specific changes or tag sequences can be introduced to any target gene. The endonucleases 
can be categorized into two groups by the mode of DNA recognition. Meganucleases, ZFNs, 
and TALENs bind specific DNA sequence through a protein-DNA interaction [38–43] 
whereas CRISPR-Cas9 is targeted to specific DNA sequence through a complementary base 
pairing involving a guide RNA (gRNA) [34, 44, 45]. The CRISPR-Cas9 genome editing has 
rapidly become the dominant technique given the relative efficiency of repair and the ease of 
genome targeting with site-specific gRNA.
While initial efforts at CRISPR-Cas9 genome editing resulted in low rates of HDR [34, 46], 
optimization efforts have led to substantial improvements in precise editing efficiencies [47]. 
Nonetheless, indels are common undesired byproduct of CRISPR-Cas9 genome editing 
since this approach depends on inducing DSBs. To reduce the formation of undesired indels 
during editing and to obviate the need for donor repair templates, a number of newer 
CRISPR-mediated base-editing methods, collectively called base editing, have been 
developed [48]. For example, Liu and colleagues developed Base Editor (BE) system, which 
utilizes a catalytically deactivated Cas9 (dCas) fused to a cytidine deaminase [49••, 50]. 
Basically, dCa9 binds to the target sequence in the genomic DNA without causing a DSB, 
and then the attached deaminase converts cytidine (C) into uridine (U). The resulting C:U 
mismatch is repaired in the cell by the mismatch base excision repair (BER) response, 
generating U:A base pair, which is subsequently converted to T:A [50]. Transfection of BE 
and a targeted gRNA can successfully convert C to T near the target sequence. Further 
refinements, such as the attachment of uracil DNA glycosylase inhibitor (UGI) to promote 
BER response, and the conversion of Cas9 to a Cas9 with nickase activity, which nicks the 
strand opposite the deaminated cytidine, have significantly increased the base-editing 
efficiency of the C > T substitution at the desired sites in the genomic DNA [48]. In 
summary, the ongoing revolution in the genome-editing technology, coupled to the equally 
revolutionary iPSC technology, offers an unprecedented opportunity for exploration of gene-
disease relationships relevant to human cardiovascular diseases and development of new 
paradigms for treating cardiovascular diseases.
Potential of Combining Genome Editing and hiPSC Technologies in 
Cardiovascular Biology
Mutations in the PRKAG2 gene, encoding the gamma-2 sub-unit of adenosine 
monophosphate kinase (AMPK), an enzyme central to cellular energy homeostasis, is 
known to a variant of familial HCM associated with an aberrant atrioventricular conduction 
[51]. These HCM mutations are known to augment glycogen storage in myocytes [52]. 
Recently, Binah and colleagues [53] utilized iPSC-CMs derived from a patient with the 
R302Q PRKAG2 mutation to examine the association between glycogen storage and 
arrhythmias seen in these patients. On TEM, the mutant iPSC-CMs displayed significant 
glycogen accumulation near mitochondria, myofibrils, and the nucleus, similar to what was 
observed in the hearts of patients with the mutant AMPK. Moreover, the mutant iPSC-CMs 
exhibited electrophysiological abnormalities, including delayed afterdepolarizations, which 
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resulted in triggered beats similar to tachyarrhythmias seen in these patients. Importantly, 
correction of the PRKAG2 mutation by CRISPR/Cas9 in the patient’s iPSCs resulted in 
iPSC-CMs that exhibited significant amelioration of both glycogen accumulation and 
electrophysiological abnormalities. This and similar studies demonstrate the power of 
combining the iPSC and the genome-editing technology for the study of human 
cardiovascular disease.
Marfan syndrome is a heritable genetic disorder of the connective tissue caused by mutations 
in the extracellular matrix protein fibrillin-1(FBN1). Sinha and colleagues generated iPSC-
derived smooth muscle cells (iPSC-SMCs) from two Marfan patients and found that the 
mutant iPSC-SMCs recapitulated pathologic characteristics seen in Marfan syndrome aortas, 
including the degradation of extracellular matrix and abnormal fibrillin-1 accumulation 
[54•]. Furthermore, CRISPR-Cas9 mediated correction of the FBN1 mutation resulted in 
correction of the Marfan disease phenotypes in iPSC-SMC, including normalization of 
fibrillin-1 accumulation, matrix degradation, and TGF-β signaling. Importantly, these 
studies demonstrated that p38, KLF4, and β1-integrin play an important role in the apoptosis 
observed in Marfan iPSC-SMCs, which suggested that p38 and KLF4 may be new 
therapeutic targets for Marfan syndrome [54•].
While this review is primarily focused on the use of the iPSC technology for modeling 
monogenic diseases, vast majority of cardiovascular diseases are multifactorial, with 
complex genetic and environmental contributions. In the past two decades, genome-wide 
association studies (GWASs) have led to hundreds of genomic loci associated with human 
diseases. However, the functional impact of individual gene variant at the individual level is 
quite small, indicating disease predisposition or susceptibility is influenced by the 
summation of multiple genetic influences. Here, patient-derived iPSCs, together with the 
CRISPR-Cas9 genomic-editing technology, will have significant impact on assessing 
functional impact of individual and groups of gene variants [55]. Another area of potential 
impact of the iPSC technology is the study of drug-induced cardiotoxicity, such as 
arrhythmias (QT prolongation and polymorphic ventricular tachycardia torsade de pointes). 
Recent study demonstrated that common gene variants associated with long QT in GWAS 
are associated with drug-induced QT prolongation and torsade de pointes, forming a basis 
for a genetic QT risk score [56]. The iPSC technology may prove valuable for functionally 
validating the contributions of these proarrhythmic risk variants and for evaluating 
proarrhythmic effects of new drugs on iPSCs reflecting genetic susceptibility in the general 
population and not necessarily in only rare proarrhythmic cohorts.
Conclusions
The two revolutions in cellular reprogramming and genome editing have opened up 
tremendous opportunities for the study of human cardiovascular disease, which had been 
hampered by limited access to live tissues. Besides the few examples discussed here, there 
are now numerous studies which have combined patient-specific iPSC-based models with 
genome editing for the personalized study of variety of cardiovascular diseases. Numerous 
hurdles remain, particularly to ensure that cardiovascular cells and tissues generated from 
human iPSCs are relevant to the study of human diseases [57, 58•, 59]. The rapid rate of 
Chun et al. Page 6





















advances in these two revolutionary technologies suggest that patient-derived and genome-
edited iPSC models may become the gold standard approach for studying cardiovascular 
diseases enabling discovery of new therapies in the future.
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